Biocon Biologics’ Yesafili (aflibercept) — indicated for age-related macular degeneration, among others — will now be accessible to Canadian patients under the province’s public insurance system. Shares of Biocon Ltd ended higher on Thursday (September 18) by 4.25% at ₹369.40 on the NSE.
